David F Hale
CIK 1024004 · Chairman · last filed 2026-01-06
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
SOMX price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
ENCINITAS, CA 92024
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Dermata Therapeutics, Inc. (DRMAW) Delisted | Director | 364 | $0.00 | $0 | $0 | 9 | 2026-01-06 |
| Oncternal Therapeutics, Inc. (ONCT) Delisted | Director | 30,387 | $0.53 | $16.0K | -$8.6K | 12 | 2024-06-24 |
| BIOCEPT INC (BIOC) Delisted | Director | 30 | $0.43 | $13 | $197.5K | 17 | 2021-12-10 |
| Histogen Inc. (CNAT) Delisted | Director | 3,636 | — | — | $28.5K | 8 | 2019-07-01 |
| SANTARUS INC (SNTS) Delisted | Director | 315,452 | — | — | $96.2K | 13 | 2013-06-12 |
| Pernix Sleep, Inc. (SOMX) Delisted | Director | 110,486 | — | — | -$289.6K | 25 | 2013-01-03 |
| MICROMET, INC. (MITI) Delisted | Director | 2,781 | — | — | -$168.3K | 15 | 2012-03-06 |
| MBRX | Director | 1 | $8.66 | $9 | $23.4K | 5 | 2009-06-25 |
Recent Filings · Page 3 of 11
107 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-06-12 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-06-09 | BIOCEPT INC (BIOC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2020-05-22 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Buy (P) | +17,412 | $0 | EDGAR |
| 2019-09-16 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-07-01 | Histogen Inc. (CNAT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-19 | BIOCEPT INC (BIOC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2019-06-11 | Oncternal Therapeutics, Inc. (ONCT) Delisted | Grant (A) | +717,752 | $0 | EDGAR |
| 2018-07-02 | BIOCEPT INC (BIOC) Delisted | Grant (A) | — | $0 | EDGAR |
| 2018-06-25 | Histogen Inc. (CNAT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-06-26 | Histogen Inc. (CNAT) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.